Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Healthwise HoldingsHKSE:00348 -6.12% Altman Z-Score is 0.32 as of Aug. 12, 2026, which is 78% below its 10-year median of 1.43. The stock has 3 warning signs investors should review. Among 656 Healthcare Providers & Services companies, China Healthwise Holdings ranks worse than 81.1% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.33 is in distress zone. This implies bankruptcy possibility in the next two years.
China Healthwise Holdings has a Altman Z-Score of 0.32, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for China Healthwise Holdings's Altman Z-Score or its related term are showing as below:
HKSE:00348'
s Altman Z-Score Range Over the Past 10 Years
Min: -2.09 Med: 1.43 Max: 7.49
Current: 0.33
During the past 13 years, China Healthwise Holdings's highest Altman Z-Score was 7.49. The lowest was -2.09. And the median was 1.43.
China Healthwise Holdings (HKSE:00348) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Healthwise Holdings Altman Z-Score Competitor Comparison
For the Pharmaceutical Retailers subindustry, China Healthwise Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Healthwise Holdings Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Healthwise Holdings's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where China Healthwise Holdings's Altman Z-Score falls into.
China Healthwise Holdings Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
China Healthwise Holdings (HKSE:00348) has a Altman Z-Score of 0.32 as of Aug. 12, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Healthwise Holdings and its competitors. This is 78% below median its historical median of 1.43. According to the industry distribution chart, China Healthwise Holdings ranks #532 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 81.1%.
Is China Healthwise Holdings' Altman Z-Score too high?
China Healthwise Holdings' current Altman Z-Score of 0.32 is 78% below median its 10-year median of 1.43. The Healthcare Providers & Services industry median Altman Z-Score is 2.43. China Healthwise Holdings' value of 0.32 is 86.8% below this industry median. Based on the distribution chart, China Healthwise Holdings ranks #532 out of 656 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does China Healthwise Holdings' Altman Z-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, China Healthwise Holdings ranks #532 out of 656 companies for Altman Z-Score. This places China Healthwise Holdings in the lower half of its industry. The industry median Altman Z-Score is 2.43. China Healthwise Holdings' value of 0.32 is 86.8% below this benchmark. While the company's 10-year median is 1.43 vs. the industry median of 2.43, China Healthwise Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.43, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Healthwise Holdings's current Altman Z-Score of 0.32 is 86.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on China Healthwise Holdings and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Healthwise Holdings's current Altman Z-Score is 0.32, which is 78% below median its own 10-year median of 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Healthwise Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Healthwise Holdings (HKSE:00348) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.09 — trading 53.3% above its estimated fair value. The current Altman Z-Score is 0.32, which is 78% below median its 10-year median of 1.43 and 86.8% below the Healthcare Providers & Services industry median of 2.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For China Healthwise Holdings (HKSE:00348), the current Altman Z-Score is 0.32 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China Healthwise Holdings Ltd is an investment holding company. It operates in three segments: Chinese health products, Money lending business, and investment in financial instruments. The majority of its revenue comes from trading in Chinese health products, which includes, pharmaceutical products, ginseng, and dried seafood products. The company's geographical segments are Hong Kong and the PRC, of which key revenue is derived from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00348 has been successfully added to your 
